CR

CorVel CorpNASDAQ CRVL Stock Report

Last reporting period 30 Sep, 2024

Updated 22 Nov, 2024

Last price

Market cap $B

5.488

Middle

Exchange

XNAS - Nasdaq

CRVL Stock Analysis

CR

Avoid

Based on Eyestock quantitative analysis, CRVL`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

116/100

High score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-43.1 %

Greatly overvalued

Market cap $B

5.488

Dividend yield

Shares outstanding

17.159 B

CorVel Corporation is engaged in applying technology, including artificial intelligence, machine learning and natural language processing designed to address the management of care and the related health-care costs. It provides a range of services, including claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care, and Medicare services. It partners with employers, third party administrators (TPAs), insurance companies, and government agencies to assist its customers in managing the medical costs of workers compensation, group health and auto insurance, and in monitoring the quality of care provided to claimants. Its network solutions services include professional nurse review, expert fee negotiations, specialty networks, preferred provider organization management, medical bill repricing, automated adjudication, and electronic reimbursement. Its bill review services include Coding review and re-bundling.

View Section: Eyestock Rating